FDA advisory panel makes favorable recommendation for ARZERRA (ofatumumab) GlaxoSmithKline and Genmab A/S announced that the United States Food and Drug Administration's Oncologic Drugs Advisory Committee voted 10 to three that the ARZERRA data are reasonably likely to predict clinical benefit for patients with chronic lymphocytic leukemia whose disease is refractory to fludarabine and alemtuzumab. [more...]
